Predictive biomarkers and preventive strategies for PTLD: a turning point in viro-immunologic precision medicine?
Refined blood tests now enable detection of previously undetectable post-transplant lymphomas, opening doors to earlier intervention and prevention strategies.
This review synthesizes the evolving PTLD biomarker landscape including ctDNA-based approaches for EBV-negative forms, a historically undetectable entity. The integration of viral, immune, and tumor-derived markers represents a paradigm shift toward viro-immunologic precision medicine for post-transplant lymphoma prevention.
What the study was
- Study design
- Narrative review with evidence synthesis
- Population
- Solid organ transplant recipients at risk for post-transplant lymphoproliferative disorder (PTLD)
- Category
- Early Detection
- Maturity
- Exploratory
- Journal
- Transplant International
Why it surfaced
PTLD is a high-unmet-need complication affecting transplant recipients; ctDNA for EBV-negative PTLD is novel; PMC open access; Strasbourg transplant immunology group has high credibility in this area.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.